Schrödinger, Inc. (SDGR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Schrödinger (SDGR) emphasized its differentiated physics-based AI platform at the Morgan Stanley conference, highlighting its capacity to generate vast, high-quality training data for machine learning, thereby accelerating novel drug discovery and addressing complex multi-parameter optimization challenges. The company noted regulatory tailwinds from the FDA's embrace of computational tools, particularly for reducing animal testing, which is driving platform adoption. Validation points include 15 molecules entering the clinic, successful collaborations like the Morphic acquisition by Lilly, and positive Phase 1 data for its MALT1 inhibitor, SGR-1505, which demonstrated a favorable safety profile and early efficacy. Strategically, SDGR plans to seek development partners for later-stage clinical programs like SGR-1505 to manage expenses and focus on its core early discovery strengths, aiming for profitability while projecting 10-15% software revenue growth driven by expanding large pharma engagements.

Analysis

Schrödinger's management presented a confident outlook, emphasizing its core competitive advantage in drug discovery through a physics-based computational platform that generates proprietary, large-scale training data for its AI models. This approach, which allows the exploration of "hundreds of billions of molecules," is positioned as superior to purely machine learning-based methods that are constrained by limited public chemical data. The platform's value is substantiated by significant external validation, including 15 partnered molecules entering the clinic and high-profile collaboration successes such as the Morphic acquisition by Lilly and a $150 million deal with Novartis. Internally, the lead asset SGR-1505, a MALT1 inhibitor, has successfully de-risked its mechanism in Phase I with a favorable safety profile and early efficacy signals, differentiating it from a failed competitor. The company's strategy is to seek a partner for SGR-1505's capital-intensive mid-to-late-stage development, framing this as a disciplined focus on its core strength in early discovery rather than a lack of confidence in the asset. This capital-light pipeline strategy is complemented by a stable and growing software business, guided for 10-15% revenue growth driven by deeper penetration within large pharma clients, where retention for contracts over $500k is near 100%. A recent $30 million reduction in operating expenses underscores a clear focus on achieving profitability while continuing to innovate, supported by regulatory tailwinds from the FDA's embrace of computational tools.

Key Decisions for Investors

• Monitor the company's progress on securing a strategic partner for the SGR-1505 program, as a successful deal with a major pharmaceutical firm would validate the asset's potential and reinforce the capital-light development strategy.
• Evaluate the execution on the 10-15% software revenue growth guidance by tracking the expansion of customer accounts with an annual contract value (ACV) over $1 million, which management has identified as the key growth engine.
• Consider the company's disciplined path toward its stated goal of profitability, which balances continued platform investment with controlled expenses, exemplified by the recent $30 million cost reduction and the out-licensing of expensive later-stage clinical assets.
• Watch for the upcoming Phase I data readout for SGR-3515 in advanced solid tumors, which represents the next significant clinical catalyst and a key test of the platform's ability to generate differentiated oncology candidates.